Long-Term Study Demonstrates Benefits Of Medtronic’s AdaptivCRT
This article was originally published in The Gray Sheet
Executive Summary
Complete results of the Adaptive CRT study released at the Heart Failure Society of America conference confirm that Medtronic’s AdaptivCRT cardiac resynchronization therapy reduces heart failure hospitalizations compared to regular echo-guided biventricular pacing.
You may also be interested in...
Medtronic Claims Clinical, Cost Advantages For Just-Launched Viva CRT-D
Viva is the first of Medtronic’s U.S. CRT-Ds to incorporate the proprietary AdaptivCRT algorithm designed to more readily adapt to a patient’s condition and optimize therapy. The firm also launched its Evera ICD last week.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.